The DOI matches its Crossref record; 100 of the 101 references it cites were found in a registry or an index.
Modifiable barriers for recruitment and retention of older adults participants from underrepresented minorities in alzheimer's disease research
Open accessAbstract
Clinical Alzheimer’s disease (AD) trials currently face a critical shortfall of thousands of eligible participants, which inflates the duration and cost of the clinical study as well as threatens the scientific merit of promising clinical interventions. This recruitment crisis is further compounded by the fact that underrepresented and marginalized populations—particularly those identifying as a racial or ethnic minority, those with low socioeconomic status, or living in rural areas—have been historically underrepresented in ongoing AD clinical trials despite overwhelming evidence that such populations are at increased risk for developing dementia. As a result of various recruitment barriers, current AD clinical studies frequently reflect a decreasingly representative segment of the US population, which threatens the overall generalizability of these findings. The current narrative review provides an updated examination and critique of common recruitment barriers and potential solutions, as well as a discussion of theoretical approaches that may address barriers disproportionately experienced by underrepresented communities. AD clinical researchers are encouraged to take purposive action aimed at increasing diversity of enrolled AD clinical trial cohorts by actively identifying and quantifying barriers to research participation—especially recruitment barriers and health disparities that disproportionately prevent underrepresented and marginalized populations from participating in research. Furthermore, researchers are encouraged to closely track which individuals who express interest in AD research ultimately enroll in research studies to examine whether AD research participation is appropriately representative of the intended population for whom these new and novel AD interventions are being designed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
EFFECTIVE RECRUITMENT AND RETENTION OF MINORITY RESEARCH PARTICIPANTS
Yancey, A. K., Ortega, A. N., & Kumanyika, S. K. (2006) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.27.021405.102113 · Cited by 1,196 · cited 1×
“questions to staff members [32, 63] stagger and reit-”
Background2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Increasing Diversity in Clinical Trials: Overcoming Critical Barriers
Clark, L. T., Watkins, L., Piña, I. L., Elmer, M., Akinboboye, O., Gorham, M., Jamerson, B., McCullough, C., Pierre, C., Polis, A. B., et al. (2019) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2018.11.002 · Cited by 731 · cited 5×
“Clinical researchers must also prioritize patient health and safety by frequently monitoring their physical and psychological health and promptly addressing any side-effects experienced by the patient [71].”
BackgroundInfluentialCrocker, J. C., Ricci-Cabello, I., Parker, A., Hirst, J. A., Chant, A., Petit-Zeman, S., Evans, D., & Rees, S. (2018) · BMJ · doi:10.1136/bmj.k4738 · Cited by 624 · cited 1×
“Difficulty in participant recruitment runs the risk of delaying treatment delivery [108] by inflating the duration and cost of the clinical study [6, 108] and has the potential to threaten the external validity of research findings [108].”
BackgroundBabulal, G. M., Quiroz, Y. T., Albensi, B. C., Arenaza‐Urquijo, E., Astell, A. J., Babiloni, C., Bahar‐Fuchs, A., Bell, J., Bowman, G. L., Brickman, A. M., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.009 · Cited by 528 · cited 7×
“Existing research has also demonstrated a difference in AD pathophysiology between African American and Caucasian populations, which may unwittingly result in underdiagnosis of AD among African Americans [91, 92].”
BackgroundInfluentialThe effect of informal care on work and wages
Van Houtven, C. H., Coe, N. B., & Skira, M. M. (2013) · Journal of Health Economics · doi:10.1016/j.jhealeco.2012.10.006 · Cited by 479 · cited 4×
“Caregivers lacking favorable attitudes towards research, fear of potential side-effects, and wish to avoid increasing patient’s burden [9, 10, 66] Provide frequent opportunities to ask clarifying questions [67, 73]; frequent opportunities to discuss risk and benefits of research participation [65]”
BackgroundInfluentialAssessment of Racial Disparities in Biomarkers for Alzheimer Disease
Morris, J. C., Schindler, S. E., McCue, L. M., Moulder, K. L., Benzinger, T. L. S., Cruchaga, C., Fagan, A. M., Grant, E., Gordon, B. A., Holtzman, D. M., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4249 · Cited by 370 · cited 5×
“Community-based providers being unaware of ongoing AD clinical trials [2]; lack of communication between community providers and researchers [74]; absence of formal training for referring providers [65]; time constraints experienced by community-based medical providers [78]; fear of losing patients to medical research…”
BackgroundResultInfluentialMody, L., Miller, D. K., McGloin, J. M., Freeman, M., Marcantonio, E. R., Magaziner, J., & Studenski, S. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.02015.x · Cited by 361 · cited 1×
“Such barriers include 1) medical and/or psychiatric disturbances [2, 31] that may increase heterogeneity in participant response to the treatment protocol and are therefore often identified as exclusionary criteria in ongoing AD research [39], 2) need for a study partner [2], 3) participant burden [40], 4) unique barr…”
Background
Research works printed but not linked: 8
- Institute of Medicine (US) (2012). The Clinical Trials Process, National Academies Press (US).
- Institute of Medicine (2010) Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary.
- Institute of Medicine (US) (2012) Public Engagement and Clinical Trials: New Models and Disruptive Technologies: Workshop Summary, National Academies Press (US), Washington (DC).
- Evelyn B, 2001, J Natl Med Assoc, 93, 18S
- Seitz DP, 2018, Cochrane Database Syst Rev, 2, CD011415
- ManlyJ, MayeuxR (2004) Ethnic differences in dementia and Alzheimer’s disease. In Critical Perspectives on Racial and Ethnic Differences in Health in Late Life , Anderson NB, Bulatao RA, Cohen B, eds. The National Academies Press, pp. 95–142.
- Assistant Secretary for Planning and Evaluation (2014), Racial and Ethnic Disparities in Alzheimer’s Disease: A Literature Review.
- Boise L, 2017, Gerontologist, 57, 719
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Detection and treatment of Alzheimer’s disease in its preclinical stage
Rafii, M. S., & Aisen, P. S. (2023) · Nature Aging · doi:10.1038/s43587-023-00410-4 · Cited by 160
Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials
Langbaum, J. B. S., Zissimopoulos, J., Au, R., Bose, N., Edgar, C. J., Ehrenberg, E., Fillit, H. M., Hill, C. V., Hughes, L., Irizarry, M. C., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12737 · Cited by 121
Representativeness of samples enrolled in Alzheimer's disease research centers
Rentería, M. A., Mobley, T. M., Evangelista, N. D., Medina, L. D., Deters, K., Fox‐Fuller, J. T., Minto, L. R., Avila‐Rieger, J. F., & Bettcher, B. M. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12450 · Cited by 88
Lim, A. C., Barnes, L. L., Weissberger, G. H., Lamar, M., Nguyen, A. L., Fenton, L. E., Herrera, J., & Han, S. D. (2023) · Communications Medicine · doi:10.1038/s43856-023-00333-6 · Cited by 90
Metadata
- Authors
- Indorewalla, K. K., O’Connor, M. K., Budson, A. E., Guess (DiTerlizzi), C., & Jackson, J.
- Affiliations
- Edith Nourse Rogers Memorial Veterans Hospital (US)
- Boston University (US)
- Boston University Alzheimer’s Disease Research Center, Department of Neurology, Boston University School of Medicine, Boston, MA, USA
- Corresponding author
- Jackson, Jonathan
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2021-02-17
- Volume
- 80
- Issue
- 3
- Pages
- 927-940
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC8150544
- OpenAlex
- W3130554957
- Cited by
- 93
- References
- 101
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 21 · 2023: 20 · 2022: 10 · 2021: 1
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01 CX001698)
- National Institute on Aging (DP1AG069873, P30AG013846)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- participant recruitment
- MeSH terms
- Alzheimer Disease, Clinical Trials as Topic, Humans, Minority Groups, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modifiable barriers for recruitment and retention of older adults participants from underrepresented minorities in alzheimer's disease research. https://app.cochat.ai/papers/10.3233/jad-201081
- The paper
- Indorewalla, K. K., O’Connor, M. K., Budson, A. E., Guess (DiTerlizzi), C., & Jackson, J. (2021). Modifiable barriers for recruitment and retention of older adults participants from underrepresented minorities in alzheimer's disease research. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-201081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.